Liver Neoplasms
Conditions
Keywords
Blood salvage therapy, Oncologic liver surgery
Brief summary
A before and after trial comparing the systematic use of blood salvage therapy with leucocyte filter during oncologic liver resections. Recurrence, survival, allogenic transfusion rates and surgical outcomes are compared with a representative historic cohort.
Detailed description
Blood salvage therapy in oncologic liver surgery is seldom used based on unproven concerns about the safety of the technique regarding potential cancer dissemination or recurrence. Nevertheless, the technique has proven advantages in other surgical settings regarding the allogenic transfusion outcomes. Allogenic blood transfusion has been scientifically proven to worsen prognosis in oncologic surgery. This study compares a cohort of patients systematically exposed the blood salvage therapy to one comparable cohort without the therapy and outcomes regarding transfusion rates, post-operative Hb measurement, recurrence, overall survival, and post-operative adverse events.
Interventions
PROCEDUREBlood salvage therapy
In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
Sponsors
Université de Sherbrooke
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Inclusion criteria
* Adult Oncologic liver surgery scheduled in our institution
Exclusion criteria
* Condition precluding consent for trial Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence free survival | 18 months | — |
| Overall survival | 18 months | — |
| Transfusion | Up to 30 days after surgery | Allogenic blood products requirements |
Countries
Canada
Outcome results
None listed